DEXCOM INC 4

Director Mark G. Foletta, via The Foletta Family Trust, sold a total of 4,000 shares of DexCom, Inc. common stock under a 10b5-1 plan for roughly $330,640 in aggregate proceeds.

On this Form 4, reporting person Mark G. Foletta, through The Foletta Family Trust, reported two automatic sales of DexCom, Inc. common stock executed under a Rule 10b5-1 trading plan adopted on March 13, 2026. The Trust sold 2,000 shares on July 31, 2026 at $80.00 per share for proceeds of approximately $160,000, followed by another 2,000-share sale on August 3, 2026 at $85.32 per share for proceeds of about $170,640, for total aggregate sale proceeds of roughly $330,640. Following these transactions, the Trust continued to hold 48,852 shares of DexCom common stock indirectly and 6,331 shares directly, implying an overall post-transaction economic interest of 55,183 shares. The filing notes that the shares are held by the Trust, for which Foletta serves as trustee, and references a separate unvested RSU award granted on May 28, 2026, which will vest on the earlier of its one-year anniversary or DexCom’s 2027 annual shareholder meeting.

Filing Facts

CIK

1093557

Ticker

DXCM

Form

4

Source Type

sec

Accession

0001093557-26-000145

Alert Tier

6